Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1977 1
1980 1
1981 4
1982 13
1983 26
1984 49
1985 84
1986 109
1987 115
1988 133
1989 160
1990 268
1991 284
1992 297
1993 414
1994 372
1995 434
1996 374
1997 356
1998 348
1999 308
2000 310
2001 390
2002 413
2003 469
2004 536
2005 579
2006 629
2007 679
2008 623
2009 664
2010 687
2011 599
2012 374
2013 388
2014 298
2015 261
2016 166
2017 153
2018 128
2019 105
2020 137
2021 101
2022 73
2023 66
2024 17

Text availability

Article attribute

Article type

Publication date

Search Results

12,266 results

Results by year

Filters applied: . Clear all
Page 1
Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study.
Gisslinger H, Klade C, Georgiev P, Krochmalczyk D, Gercheva-Kyuchukova L, Egyed M, Rossiev V, Dulicek P, Illes A, Pylypenko H, Sivcheva L, Mayer J, Yablokova V, Krejcy K, Grohmann-Izay B, Hasselbalch HC, Kralovics R, Kiladjian JJ; PROUD-PV Study Group. Gisslinger H, et al. Lancet Haematol. 2020 Mar;7(3):e196-e208. doi: 10.1016/S2352-3026(19)30236-4. Epub 2020 Jan 31. Lancet Haematol. 2020. PMID: 32014125 Clinical Trial.
BACKGROUND: The PROUD-PV and CONTINUATION-PV trials aimed to compare the novel monopegylated interferon ropeginterferon alfa-2b with hydroxyurea, the standard therapy for patients with polycythaemia vera, over 3 years of treatment. ...Median follow-up was 182 …
BACKGROUND: The PROUD-PV and CONTINUATION-PV trials aimed to compare the novel monopegylated interferon ropeginterferon alfa- …
Interferon alfa-2b in patients with low-grade lymphomatoid granulomatosis and chemotherapy with DA-EPOCH-R in patients with high-grade lymphomatoid granulomatosis: an open-label, single-centre, phase 2 trial.
Melani C, Dowdell K, Pittaluga S, Dunleavy K, Roschewski M, Song JY, Calattini S, Kawada JI, Price DA, Chattopadhyay PK, Roederer M, Lucas AN, Steinberg SM, Jaffe ES, Cohen JI, Wilson WH. Melani C, et al. Lancet Haematol. 2023 May;10(5):e346-e358. doi: 10.1016/S2352-3026(23)00029-7. Epub 2023 Mar 31. Lancet Haematol. 2023. PMID: 37011643 Clinical Trial.
FINDINGS: 67 patients were enrolled between Jan 10, 1991, and Sept 5, 2019 (42 [63%] were male). 45 patients received initial treatment with interferon alfa-2b (16 of whom crossed over to DA-EPOCH-R) and 18 received initial treatment with DA-EPOCH-R (eight of …
FINDINGS: 67 patients were enrolled between Jan 10, 1991, and Sept 5, 2019 (42 [63%] were male). 45 patients received initial treatment with …
Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trial.
Barbui T, Vannucchi AM, De Stefano V, Masciulli A, Carobbio A, Ferrari A, Ghirardi A, Rossi E, Ciceri F, Bonifacio M, Iurlo A, Palandri F, Benevolo G, Pane F, Ricco A, Carli G, Caramella M, Rapezzi D, Musolino C, Siragusa S, Rumi E, Patriarca A, Cascavilla N, Mora B, Cacciola E, Mannarelli C, Loscocco GG, Guglielmelli P, Betti S, Lunghi F, Scaffidi L, Bucelli C, Vianelli N, Bellini M, Finazzi MC, Tognoni G, Rambaldi A. Barbui T, et al. Lancet Haematol. 2021 Mar;8(3):e175-e184. doi: 10.1016/S2352-3026(20)30373-2. Epub 2021 Jan 18. Lancet Haematol. 2021. PMID: 33476571 Clinical Trial.
This study aimed to compare the efficacy and safety of ropeginterferon alfa-2b on top of the standard phlebotomy regimen with phlebotomy alone. ...Patients randomly allocated to the experimental group received ropeginterferon alfa-2b subcutaneously eve …
This study aimed to compare the efficacy and safety of ropeginterferon alfa-2b on top of the standard phlebotomy regimen with …
Interferon-alfa-2b for meningioma.
Wöber-Bingöl C, Wöber C, Marosi C, Prayer D. Wöber-Bingöl C, et al. Lancet. 1995 Feb 4;345(8945):331. doi: 10.1016/s0140-6736(95)90326-7. Lancet. 1995. PMID: 7837901 No abstract available.
Ropeginterferon alfa-2b every 2 weeks as a novel pegylated interferon for patients with chronic hepatitis B.
Huang YW, Hsu CW, Lu SN, Yu ML, Su CW, Su WW, Chien RN, Hsu CS, Hsu SJ, Lai HC, Qin A, Tseng KC, Chen PJ. Huang YW, et al. Hepatol Int. 2020 Dec;14(6):997-1008. doi: 10.1007/s12072-020-10098-y. Epub 2020 Oct 24. Hepatol Int. 2020. PMID: 33099752 Free PMC article. Clinical Trial.
BACKGROUND: Ropeginterferon alfa-2b is a novel mono-pegylated interferon that has only one major form as opposed to 8-14 isomers of other on-market pegylated interferon, allowing injection every two or more weeks with higher tolerability. ...CONCLUSION …
BACKGROUND: Ropeginterferon alfa-2b is a novel mono-pegylated interferon that has only one major form as opposed to 8-1 …
Interferon Alfa-2b for Pigmented Ocular Surface Squamous Neoplasia: A Report of 8 Lesions.
Kaliki S, Sharma A, Vempuluru VS. Kaliki S, et al. Cornea. 2021 Feb 1;40(2):142-146. doi: 10.1097/ICO.0000000000002350. Cornea. 2021. PMID: 32355112
PURPOSE: To study the efficacy of interferon alfa-2b (IFN-a2b) on pigmented ocular surface squamous neoplasia (p-OSSN) and assess the resolution of the pigment to the treatment. ...
PURPOSE: To study the efficacy of interferon alfa-2b (IFN-a2b) on pigmented ocular surface squamous neoplasia (p-OSSN) …
Combination Interferon alfa-2b/ribavirin therapy for the treatment of hepatitis C: nursing implications.
Birkel A, Caldwell L, Stafford-Fox V, Casarico B, Benson L. Birkel A, et al. Gastroenterol Nurs. 2000 Mar-Apr;23(2):55-62. doi: 10.1097/00001610-200003000-00002. Gastroenterol Nurs. 2000. PMID: 11111599 Review.
The combination of recombinant interferon alfa-2b/ribavirin therapy increases hepatitis C viral clearance 10-fold in hepatitis C relapse patients and almost threefold in previously untreated patients compared with alpha interferon monotherapy. ...Ribav …
The combination of recombinant interferon alfa-2b/ribavirin therapy increases hepatitis C viral clearance 10-fold in he …
Interferon Alfa 2b for Ocular Surface Squamous Neoplasia: Factors Influencing the Treatment Response.
Kaliki S, Bejjanki KM, Desai A, Mohamed A. Kaliki S, et al. Semin Ophthalmol. 2019;34(7-8):465-472. doi: 10.1080/08820538.2019.1648691. Epub 2019 Aug 1. Semin Ophthalmol. 2019. PMID: 31370766
PURPOSE: To study the factors influencing the response to treatment with interferon alfa 2b (IFN) in ocular surface squamous neoplasia (OSSN)Methods: Retrospective study of 91 patientsResults: The mean age at presentation of patients with OSSN was 58 years (m …
PURPOSE: To study the factors influencing the response to treatment with interferon alfa 2b (IFN) in ocular surface squ …
Comparative therapeutic efficacy of interferon alfa-2b and combination lopinavir/ritonavir plus interferon alfa-2b against SARS-CoV-2.
Liu J, Du C, Pu L, Xiang P, Xiong H, Xie W, Chen Z, Li A. Liu J, et al. BMC Infect Dis. 2021 Aug 30;21(1):885. doi: 10.1186/s12879-021-06595-6. BMC Infect Dis. 2021. PMID: 34461841 Free PMC article.
The use of antiviral drugs in patients with this disease have triggered people's attentions. Whether interferon alfa-2b or lopinavir/ritonavir (LPV/r) plus interferon alfa-2b treatment can against SARS-CoV-2 was unknown. The objectives of …
The use of antiviral drugs in patients with this disease have triggered people's attentions. Whether interferon alfa-2b
Patient management strategies for interferon alfa-2b as adjuvant therapy of high-risk melanoma.
Donnelly S. Donnelly S. Oncol Nurs Forum. 1998 Jun;25(5):921-7. Oncol Nurs Forum. 1998. PMID: 9644709 Review.
PURPOSE/OBJECTIVES: To review results of Eastern Cooperative Oncology Group (ECOG) trial E1684 in the context of nursing issues concerning interferon alfa-2b (IFN alpha-2b) as adjuvant therapy for high-risk melanoma. ...With appropriate patient managem …
PURPOSE/OBJECTIVES: To review results of Eastern Cooperative Oncology Group (ECOG) trial E1684 in the context of nursing issues concerning …
12,266 results
You have reached the last available page of results. Please see the User Guide for more information.